DATE: September 24, 2019
TIME: 10:00 AM EDT
LOCATION: Kentucky Board of Nursing Office, Louisville, KY

I. Call to Order – Dina Byers, PhD, APRN, ACNS-BC, Chairperson
   A. Introductions
   B. Adoption of Flexible Agenda

II. Old Business:
   A. APRN Council Meeting Report – February 7, 2019 (Attachment 2A-1)

   B. Role of CRNA Independent Practice of Ordering and Performing Cosmetic and Dermatological Procedures
      a. Staff Report (Attachment 2B-1)
      b. AOS #35 Cosmetic and Dermatological Procedures by Nurses (Attachment 2B-2)
      c. Blueprint - APRN Roles Chart (Attachment 2B-3)
      d. Blueprint – DNP Course Chart (Attachment 2B-4)
      e. Blueprint - APRN Certification Chart (Attachment 2B-5)
      f. Blueprint - Requirements for Certification with the Dermatological Association of Nurses Certification (DNA) and the Plastic Surgical Nursing Certification Board (psncb) -- Email Regarding DNA DCNP Requirements (Attachment 2B-6)
      g. Blueprint Courses for Dermatology and Cosmetology (Attachment 2B-7)
      h. APRN Consensus Model for APRN Regulation (Attachment 2B-8)
      i. AANP - Scope of Practice for Nurse Practitioners (Attachment 2B-9)
      j. Excerpts from Population Focus NP Comps 2013 (Attachment 2B-10)
      k. AANA - Scope of Nurse Anesthesia Practice (Attachment 2B-11)
      l. AANA – Standards for Nurse Anesthesia Practice 2019 (Attachment 2B-12)
      m. AANA – Code of Ethics for the Certified Registered Nurse Anesthetist (Attachment 2B-13)
      n. AANA - Considerations for Adding New Activities to Individual CRNA Scope of Practice (Attachment 2B-14)
      o. Certified Registered Nurse Anesthetist Fact Sheet (Attachment 2B-15)
      p. 2017 NCSBN Round Table Transcript: Defending Your Lane, the Misaligned APRN (Attachment 2B-16)
      q. NCSBN Survey – CRNA Scope of Practice (Attachment 2B-17)
      r. Email from National Association of Nurse Anesthetist (Attachment 2B-18)
      s. Letter from the Kentucky Association of Nurse Anesthetists (Attachment 2B-19)
C. AOS #37 – Role of the Advanced Practice Registered Nurse in the Prescribing of Medications to Self and/or Family
   a. Staff Report (Attachment 2C-1)
   b. Blueprint State-by-State Comparison – Controlled Substance Prescribing to Self and/or Family (Attachment 2C-2)
   c. NCSBN Survey (Attachment 2C-3)
   d. Virginia 18 VAC 90:40 (Attachment 2C-4)
   e. Connecticut General Statutes 21a-252 (Attachment 2C-5)
   f. New Hampshire Board of Medicine Guidelines for Self-Prescribing for Family Members (Attachment 2C-6)
   g. American Medical Association (AMA) Code of Medical Ethics Opinion 1.2.1 (Attachment 2C-7)
   h. Department of Justice, Drug Enforcement Administration 84 FR 5479 (2019) (Attachment 2C-8)
   i. Irish Healthcare: Is It Caring for a Rare Disease? (Attachment 2C-9)
   j. Should Physicians Self-Prescribing be Restricted by Law? (Attachment 2C-10)
   k. The Pitfalls of Prescribing for Family and Friends (Attachment 2C-11)
   l. AOS #37 Role of the Advanced Practice Registered Nurse in the Prescribing of Medications to Self and/or Family (Attachment 2C-12)
   m. Proposed Amendment of 201 KAR 20:057 Scope and Standards of Practice of Advanced Practice Registered Nurses (Attachment 2C-13)

III. New Business:
   B. Review of 2019 – 2020 APRN Council Scope and Functions (Attachment 3B-1)
   C. Review of 2019 – 2020 Objectives (Attachment 3C-1)
   D. Cannabidiol – CBD Oil
      a. Staff Report (Attachment 3D-1)
      b. Cannabidiol : Promise and Pitfalls Article (Attachment 3D-2)
      c. The Legal Status of Cannabis (Marijuana) and Cannabidiol (CBD) under US Law (Attachment 3D-3)
      d. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy (Attachment 3D-4)
      e. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series (Attachment 3D-5)
      f. CBD-Enriched Medical Cannabis for Intractable Pediatric Epilepsy. The Current Israeli Experience (Attachment 3D-6)
      g. Cannabidiol The Need for More Information about its Potential Benefits and Side Effects (Attachment 3D-7)
      h. Statement of Principles on Industrial Hemp A Notice by the Agriculture Department, the Drug Enforcement Administration and the Food and Drug Administration on 8/12/2016 (Attachment 3D-8)
      i. Information Regarding Over-the-Counter Dietary Supplement Hemp Oil and False Positive Drug Screens (Attachment 3D-9)
      j. Can I Fail a Drug Screen when using Ananda Professional? (Attachment 3D-10)
      k. CBD and Our Endocannabinoid System (Attachment 3D-11)
      l. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals with Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial (Attachment 3D-12)
      m. Making a Case for CBD as a Treatment for Opioid Addiction (Attachment 3D-13)
      n. As CBD Oils Become More Popular, The FDA Considers Whether to Set
New Rules (Attachment 3D-14)

o. What is CBD Oil – and Should You Use it? (Attachment 3D-15)

p. FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers (Attachment 3D-16)

q. Does CBD Oil Work for Chronic Pain Management (Attachment 3D-17)

IV. Informational Items**

A. Trends in Practice Inquiries
   a. Staff Report (Attachment 4A-1)

B. Legislative Update**
   b. New Section of KRS 218A Created - Electronic Prescribing of Controlled Substances
      • KRS 218A.171 Electronic Prescribing Effective until January 1, 2020 (Attachment 4B-2)
      • KRS 218A.171 Electronic Prescribing Effective January 1, 2020 (Attachment 4B-3)
   c. Certified Professional Midwives Advisory Council Statutes KRS 314.400
      The first meeting of the CPM Advisory Council was held on September 19, 2019.

C. Kentucky Board of Pharmacy UTI Protocol
   a. Staff Report (Attachment 4C-1)
   b. Email from Anthony Gray, General Counsel, Kentucky Board of Pharmacy (Attachment 4C-2)
   c. Kentucky Board of Pharmacy - Board Approved Protocol – Acute, Uncomplicated Urinary Tract Infection Treatment Protocol (Attachment 4C-3)

D. Informational Documents

V. Other

VI. Adjournment

* Enclosed for Council Members

** Oral or written report to be given at time of meeting

Prepared by: Myra Goldman, APRN, APRN Education & Practice Consultant
               Michelle Gary, Practice Assistant Continuing Competency Coordinator

Reviewed by: Dina Byers, PhD, APRN, ACNS-BC, APRN Council Chairperson

All materials, other than this agenda, are confidential until acted upon by the Board and should not be disclosed without the advice of the KBN General Counsel.
All meetings are open to the public. Should you have any questions, please contact Myra Goldman at myrak.goldman@ky.gov or call 502-429-3315 or 800-305-2042, Ext 3315.